171 related articles for article (PubMed ID: 17092842)
1. Water-soluble HPMA copolymer--prostaglandin E1 conjugates containing a cathepsin K sensitive spacer.
Pan H; Kopecková P; Wang D; Yang J; Miller S; Kopecek J
J Drug Target; 2006 Jul; 14(6):425-35. PubMed ID: 17092842
[TBL] [Abstract][Full Text] [Related]
2. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
3. Self-association properties of HPMA copolymers containing an amphipathic heptapeptide.
Ding H; Kopecková P; Kopecek J
J Drug Target; 2007; 15(7-8):465-74. PubMed ID: 17671893
[TBL] [Abstract][Full Text] [Related]
4. Release of prostaglandin E(1) from N-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells.
Pan H; Liu J; Dong Y; Sima M; Kopecková P; Brandi ML; Kopecek J
Macromol Biosci; 2008 Jul; 8(7):599-605. PubMed ID: 18401866
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors.
Wang D; Pechar M; Li W; Kopecková P; Brömme D; Kopecek J
Biochemistry; 2002 Jul; 41(28):8849-59. PubMed ID: 12102627
[TBL] [Abstract][Full Text] [Related]
6. Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates.
Pan H; Kopecková P; Liu J; Wang D; Miller SC; Kopecek J
Pharm Res; 2007 Dec; 24(12):2270-80. PubMed ID: 17899324
[TBL] [Abstract][Full Text] [Related]
7. HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics.
Vicent MJ; Manzanaro S; de la Fuente JA; Duncan R
J Drug Target; 2004; 12(8):503-15. PubMed ID: 15621676
[TBL] [Abstract][Full Text] [Related]
8. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
[TBL] [Abstract][Full Text] [Related]
9. Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.
Kasuya Y; Lu ZR; Kopecková P; Tabibi SE; Kopecek J
Pharm Res; 2002 Feb; 19(2):115-23. PubMed ID: 11883637
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
11. N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation.
Searle F; Gac-Breton S; Keane R; Dimitrijevic S; Brocchini S; Sausville EA; Duncan R
Bioconjug Chem; 2001; 12(5):711-8. PubMed ID: 11562189
[TBL] [Abstract][Full Text] [Related]
12. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
13. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
14. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
[TBL] [Abstract][Full Text] [Related]
15. Structural and chemical aspects of HPMA copolymers as drug carriers.
Ulbrich K; Subr V
Adv Drug Deliv Rev; 2010 Feb; 62(2):150-66. PubMed ID: 19931329
[TBL] [Abstract][Full Text] [Related]
16. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
17. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.
Duncan R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1131-48. PubMed ID: 19699249
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
[TBL] [Abstract][Full Text] [Related]
19. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Omelyanenko V; Kopecková P; Gentry C; Kopecek J
J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
[TBL] [Abstract][Full Text] [Related]
20. HPMA copolymer-cyclic RGD conjugates for tumor targeting.
Pike DB; Ghandehari H
Adv Drug Deliv Rev; 2010 Feb; 62(2):167-83. PubMed ID: 19951733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
